While IDO levels are elevated in certain tumors, several inhibitors that are designed to block the activity of IDO1 have failed in clinical trials26, suggesting that a more complex and potentially tissue-specific role for Trp and its metabolites may be involved in tumor growth. The gene discussed is IDO1; the disease is neoplasm.